FDA Approves Rusfertide for Polycythemia Vera
FDA Approves Rusfertide for Polycythemia Vera OncLive
August 2026
Behind the FDA Approval: Daraxonrasib Delivers in Pancreatic Cancer
Behind the FDA Approval: Daraxonrasib Delivers in Pancreatic Cancer Targeted Oncology
FDA approves new COVID vaccines
FDA approves new COVID vaccines CIDRAP
FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood Disorder
The U.S. Food and Drug Administration today approved Mimrylo (rusfertide), a new treatment for adults with polycythemia vera, a rare…